BioPharma Credit PLC

BPCR:LSE

BioPharma Credit PLC

Actions
  • Price (USD)0.97
  • Today's Change-0.004 / -0.41%
  • Shares traded428.63k
  • 1 Year change+2.00%
  • Beta0.2634
Data delayed at least 20 minutes, as of Dec 02 2022 17:06 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year BioPharma Credit PLC's revenues fell -5.59% from 110.01m to 103.86m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 89.14m to 84.96m, a -4.69% decrease.
Gross margin87.57%
Net profit margin85.21%
Operating margin85.21%
Return on assets7.88%
Return on equity7.90%
Return on investment7.90%
More ▼

Cash flow in USDView more

In 2021, cash reserves at BioPharma Credit PLC fell by 98.56m. However, the company earned 96.44m from its operations for a Cash Flow Margin of 92.85%. In addition the company used 94.82m on investing activities and also paid 100.16m in financing cash flows.
Cash flow per share--
Price/Cash flow per share--
Book value per share1.01
Tangible book value per share1.01
More ▼

Balance sheet in USDView more

BioPharma Credit PLC has little financial risk as the capital structure does not rely on leverage.
Current ratio14.07
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -4.69%.
Div yield(5 year avg)4.15%
Div growth rate (5 year)--
Payout ratio (TTM)47.83%
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
17.04
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.